These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 35059253)

  • 1. Cross sectional study on proportion of sulfonylureas among various oral antidiabetic drugs using for Japanese patients with type 2 diabetes, analyzed from NSAID Study-2.
    Arai K; Nishikawa T; Shirabe SI; Matsuzawa Y; Ohtsu S; Yuasa S; Hirao K; Mori H
    Diabetol Int; 2022 Jan; 13(1):169-176. PubMed ID: 35059253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients.
    Arai K; Matoba K; Hirao K; Matsuba I; Takai M; Takeda H; Kanamori A; Yamauchi M; Mori H; Terauchi Y
    Endocr J; 2010; 57(6):499-507. PubMed ID: 20208396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of oral antidiabetic drug prescribing patterns based on the body mass index for Japanese type 2 diabetes mellitus patients and yearly changes in diabetologists' prescribing patterns from 2002 to 2019 (JDDM61).
    Yagi N; Komiya I; Arai K; Oishi M; Fukumoto Y; Shirabe S; Yokoyama H; Yamazaki K; Sugimoto H; Maegawa H;
    J Diabetes Investig; 2022 Jan; 13(1):65-73. PubMed ID: 34191401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nationwide Survey on Actual Interventions for Type 2 Diabetes by Japanese Practitioners (NSAID Study-1): Glycemic, Weight, and Blood Pressure Management.
    Arai K; Nishikawa T; Yuasa S; Shirabe SI; Matsuzawa Y; Ohtsu S; Hirao K; Mori H
    Diabetes Ther; 2020 Jul; 11(7):1497-1511. PubMed ID: 32440836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002-2011 in Japan (JDDM32).
    Oishi M; Yamazaki K; Okuguchi F; Sugimoto H; Kanatsuka A; Kashiwagi A;
    J Diabetes Investig; 2014 Sep; 5(5):581-7. PubMed ID: 25411627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND): study design and baseline characteristics of patients with type 2 diabetes newly initiating oral antidiabetic drug monotherapy in Japan.
    Yabe D; Higashiyama H; Kadowaki T; Origasa H; Shimomura I; Watada H; Tobe K; Iglay K; Tokita S; Seino Y
    BMJ Open Diabetes Res Care; 2020 Nov; 8(2):. PubMed ID: 33188008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus.
    Seino Y; Inagaki N; Haneda M; Kaku K; Sasaki T; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
    J Diabetes Investig; 2015 Jul; 6(4):443-53. PubMed ID: 26221523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33).
    Yokoyama H; Hirao K; Yamaguchi K; Oishi M; Lee G; Yagi N; Takamura H; Kashiwagi A
    Jpn Clin Med; 2014; 5():33-41. PubMed ID: 25288908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Present status of insulin therapy for type 2 diabetes treated by general practitioners and diabetes specialists in Japan: Third report of a cross-sectional survey of 15,652 patients.
    Arai K; Takai M; Hirao K; Matsuba I; Matoba K; Takeda H; Kanamori A; Yamauchi M; Mori H; Terauchi Y
    J Diabetes Investig; 2012 Aug; 3(4):396-401. PubMed ID: 24843596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients.
    Kubota A; Maeda H; Kanamori A; Matoba K; Jin Y; Minagawa F; Obana M; Iemitsu K; Ito S; Amamiya H; Kaneshiro M; Takai M; Kaneshige H; Hoshino K; Ishikawa M; Minami N; Takuma T; Sasai N; Aoyagi S; Kawata T; Mokubo A; Takeda H; Honda S; Machimura H; Motomiya T; Waseda M; Naka Y; Tanaka Y; Terauchi Y; Matsuba I
    J Diabetes Investig; 2012 Dec; 3(6):503-9. PubMed ID: 24843615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy.
    Lorenzoni V; Baccetti F; Genovese S; Torre E; Turchetti G
    Clinicoecon Outcomes Res; 2017; 9():699-710. PubMed ID: 29200879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.
    Baxter M; Morimoto Y; Tamiwa M; Hattori M; Peng XV; Lubwama R; Maegawa H
    Diabetes Ther; 2020 Jul; 11(7):1481-1496. PubMed ID: 32445125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in Dental Care Referral for Diabetic Patients Between General Practitioners and Diabetes Specialists in Japan, Analyzed from NSAID-Study 3.
    Arai K; Nishikawa T; Matsuzawa Y; Ohtsu S; Shirabe SI; Yuasa S; Hirao K; Mori H
    Diabetes Ther; 2022 Feb; 13(2):379-385. PubMed ID: 34958439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient characteristics associated with improvement in glycemic control following addition of an oral antidiabetic drug to DPP-4 inhibitor monotherapy in Japanese patients with type 2 diabetes mellitus (JDDM 60).
    Kawai K; Eiki JI; Kanatsuka A; Motohashi S; Wakana A; Hayashi A; Iglay K; Yamazaki K; Tokita S; Maegawa H;
    Diabetol Int; 2022 Jan; 13(1):132-141. PubMed ID: 35059249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination Therapy with a Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Metformin Markedly Improves HbA1c Levels in Japanese Patients with Type 2 Diabetes Mellitus.
    Hirao K; Maeda H; Shirabe S; Yamamoto R; Hirao T; Hirao S; Yamauchi M; Arai K
    Jpn Clin Med; 2012; 3():1-7. PubMed ID: 23946679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life effectiveness and tolerability of vildagliptin and other oral glucose-lowering therapies in patients with type 2 diabetes in Germany.
    Göke R; Bader G; Dworak M
    Diabetes Ther; 2014 Jun; 5(1):183-91. PubMed ID: 24643724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.
    Ragia G; Petridis I; Tavridou A; Christakidis D; Manolopoulos VG
    Pharmacogenomics; 2009 Nov; 10(11):1781-7. PubMed ID: 19891554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy.
    Bell DS
    Clin Ther; 2004 Nov; 26(11):1714-27. PubMed ID: 15639686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Patterns of Antidiabetic Medication Use in Patients with Type 2 Diabetes.
    Xu Y; Yang Z; Lin H; Shen P; Wang H; Zhan S
    Med Sci Monit; 2018 Dec; 24():8707-8715. PubMed ID: 30504761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in the use of oral antidiabetic drugs by outpatients in Taiwan: 1997-2003.
    Chiang CW; Chiu HF; Chen CY; Wu HL; Yang CY
    J Clin Pharm Ther; 2006 Feb; 31(1):73-82. PubMed ID: 16476123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.